<DOC>
	<DOCNO>NCT02571166</DOCNO>
	<brief_summary>The purpose study determine safety HSV529 vaccine healthy volunteer HSV infection determine administration HSV529 vaccine increase immune response genital skin .</brief_summary>
	<brief_title>HSV529 Vaccine HSV-2 Seropositive Adults</brief_title>
	<detailed_description>The investigator enroll cohort 8-10 HIV-1 seronegative , HSV-2 seropositive person recurrent genital HSV-2 lesion area amenable genital biopsy . Participants enroll genital lesion . They undergo lesion biopsy non-lesion biopsy . They start suppressive valacyclovir 500 mg po daily 4 week . Three day completion 4 week valacyclovir course , participant initiate vaccination HSV529 0 , 1 , 6 month dose schedule . At vaccination visit 10 day post vaccination visit , genital biopsy perform . Genital biopsy perform site genital lesion non-lesional genital site . PBMC also draw . Two day second vaccination , optional biopsy offer . Overall , minimum 14 genital biopsy perform participant : 7 genital lesion site , 7 genital non-lesion site . Four control biopsy upper arm also perform . For participant undergo optional biopsy two day Dose 2 , two additional genital biopsy perform . Participants also collect daily genital swab HSV PCR 30 day vaccination .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<criteria>1 . HSV2 seropositive UW Western blot history recurrent genital herpes , lesion area amenable biopsy . 2 . Aged 18 55 year day enrollment . 3 . In good general health absence significant health problem determine medical history , physical examination , laboratory screening perform screen visit . 4 . Hemoglobin , hematocrit , white blood cell count , platelet count , serum creatinine , liver function ( ALT , AST , alkaline phosphatase , total bilirubin ) screen laboratory result fall range value Grade 1 great per toxicity grade scale . 5 . Female subject must nonchildbearing potential i.e . surgically sterilize ( bilateral tubal ligation , hysterectomy ) , childbearing potential sexually active male partner , must willing use highly effective method contraception ( e.g. , intrauterine device ( IUD ) ; oral contraceptive , diaphragm condom combination contraceptive foam , jelly cream ; Norplant , DepoProvera , contraceptive skin patch cervical ring ) least 30 day prior vaccination 30 day final vaccination monogamous relationship male partner undergone vasectomy least 6 month prior first dose HSV529 . 6 . Willingness attend schedule visit able comply trial procedure ( e.g. , blood draw , biopsy , completion diary card , return followup visit , accessible phone pager , able selfsample assessment asymptomatic shed HSV , plan move study area ) . 7 . HIV seronegative . 8 . Subject willing use antiviral therapy 3 day injection swab period . If recurrence occur swab period , participant ask NOT take antiviral therapy . 9 . Subject willing forgo receipt license , live vaccine 30 day precede dose vaccine 30 day follow dose vaccine . The inactivated flu vaccine use ≥14 day ≥14 day administration study vaccine , felt necessary . 10 . Persons close contact infant immunocompromised individual willing avoid contact 3 day injection . 1 . Subject pregnant nursing OR planning become pregnant timeframe begin 30 day prior first vaccination end 30 day third vaccination . 2 . Body Mass Index great 35 . 3 . Hepatitis C seropositive 4 . Hepatitis B surface antigen positive 5 . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination plan participation study period 6 month last dose vaccine . The noninterventional followup earlier study ( e.g. , longterm surveillance ) allow . 6 . Severe active infection serious HSV2 relate unrelated medical condition , opinion investigator , would prevent study completion . 7 . Subjects 9 symptomatic recurrence genital herpes disease within year prior Day 0 . 8 . A history HSV infection eye ( e.g. , herpes simplex interstitial keratitis uveitis ) . 9 . A history herpes gladiatorum , herpetic whitlow eczema herpeticum . 10 . A history lesion cause HSV either arm . 11 . A history herpesassociated erythema multiforme . 12 . A history clinically significant autoimmune disorder . 13 . Known suspected congenital acquire immunodeficiency . 14 . Receipt anticancer chemotherapy radiation therapy within precede 6 month . 15 . Subjects use corticosteroid ( exclude topical , inhale nasal ) immunomodulating drug ( see Prohibited Medications Section ) within 42 day prior first vaccination . An immunosuppressive dose corticosteroid define ≥10 mg prednisone equivalent per day &gt; 14 day . 16 . Subjects without spleen . 17 . Subjects receive immunoglobulin within past 6 month anticipate receipt immunoglobulin 28 day follow vaccination . 18 . Bleeding disorder , receipt anticoagulant , opinion Investigator , would interfere subject 's participation trial . 19 . Known allergy intolerance vaccine component [ e.g. , potassium glutamate ( possible crossreaction monosodium glutamate ) , sucrose ] vaccine contain substance . 20 . Known allergy intolerance silver nitrate lidocaine . 21 . Known allergy intolerance acyclovir valacyclovir . 22 . Chronic illness , opinion Investigator , stage might interfere trial conduct completion . 23 . History keloid formation excessive scarring . 24 . History frequent cellulitis boil ( &gt; 3 episode past 2 year ) require antibiotic therapy . 25 . Prior receipt HSV vaccine . 26 . Any condition PI think might compromise person 's ability comply requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>